Hemab
Business Services · Denmark · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Nordre Fasanvej 215, Frederiksberg, Regi...Website
www.hemab.comRevenue
-Industry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
2
1
1
1
About Hemab
Hemab is a multiple clinical-asset biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Based in Cambridge, MA, and Copenhagen, Denmark, Hemab is progressing a pipeline of innovative therapeutic solutions, leveraging a variety of cutting-edge technologies and approaches to transform the treatment paradigm for patients with high unmet need.Explore more
Hemab Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Hemab your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Hemab has new funding data
Check if Hemab has recently received funding, and reach out quickly before it becomes old news!
Hemab, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Hemab is spiking on competitors!
Click to see if Hemab had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Hemab launches new products
Congratulate Masked Content for being promoted to Masked Content at Hemab
Earning: See what the market has to say on Hemab recently announced quarterly report
Recommended Actions
Find VP level buyers at Hemab
Find more new buyers
Compare Similar Companies to Hemab
Compare insights from companies similar to Hemab, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Hemab is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Hemab is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Hemab.
Hemab financials insights
Gather financial insights about Hemab, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$55M
2023
Series B
$135M
2025
Series C
$157M
2026
IPO
$301.5M
Hemab Tech Stack
A closer look at the technologies used by Hemab
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Initial Public Offering (IPO)
IPO, Finance
Funding
IPO, Funding
Hemab News & Media
Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress
HMB-002 clinical data demonstrate proof of mechanism, with dose-dependent, greater than or equal to 2.4-fold peak increases in Von Willebrand Factor (VWF) and Factor VIII (FVIII), normalization of peak thrombin generation and activated partial thromboplastin time (APTT), and durability supporting potential monthly subcutaneous dosingHemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress
New results from HMB-002 first-in-human data validate proof of mechanism in Von Willebrand disease (VWD), elevating Von Willebrand Factor (VWF) and Factor VIII (FVIII) levels with subcutaneous dosing; multiple dose assessment underwayHemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 27, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced that members of the Hemab Therapeutics management team will present and host investor meetings at the 2026 Jefferies Global Healthcare Conference.Hemab Therapeutics Reports First Quarter 2026 Financial Results
Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Hemab
Sign Up For FreeTo access detailed company insights
Hemab is a multiple clinical-asset biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Based in Cambridge, MA, and Copenhagen, Denmark, Hemab is progressing a pipeline of innovative therapeutic solutions, leveraging a variety of cutting-edge technologies and approaches to tran... Read More
